Galectin Therapeutics Inc. (OTC:GALT) is rushing down this week. Yesterday, the stock lost another 3.06% of its price, while its 
traded volume flew up unexpectedly.
However, the strangest thing here is that while the downtrend continues, the reason for the price fall cannot be found.
Historical data shows that Galectin has not released any news on its business lately, thus no one has a clue about its current operations. Though, it is not certain if this is the explanation of the recent losses.
The last news on GALT dates from Dec 19, when the company released an update on its activities. According to the update, Galectin was pleased with the progress it has made in its mission to create new therapeutics based on its work in the area of galectin inhibition.
In addition, the company stated that they were proud of their accomplishments in the period since the mid-year implementation of a refined corporate strategy.
Being released, the positive statements pushed up GALT stock price for a few days, though the climb was shortly broken.
Last month, Galectin filed its quarterly report. However, it was completely discouraging.[BANNER]
As of September 30, GALT still had some cash and cash equivalents in its balance, however, its deficit accumulated during the development stage kept increasing. At the same time, the company’s net loss and its expenses jumped up as well.
Despite its poor financials, the management of Galentin believes that they have sufficient cash to fund the core operations through the first quarter of 2013. Nevertheless, they claim that GALT will require additional financing to fund its future operations, while their business hides numerous risk factors.
